发布时间：2026-04-24 10:33 Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents
A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designation
The program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs



CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast a
=*=*=*=*=*=
当前为第1/7页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页